Correlation Engine 2.0
Clear Search sequence regions


  • 1- butanol (3)
  • ci 2 (1)
  • cohort study (1)
  • donor (11)
  • graft (9)
  • humans (1)
  • lung (6)
  • lung transplant (3)
  • mortality (5)
  • probability (1)
  • risk factor (1)
  • smoking (10)
  • tobacco (1)
  • Sizes of these terms reflect their relevance to your search.

    Rationale: Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation. Prior studies implicated proxy-defined donor smoking as a risk factor for PGD and mortality. Objectives: We aimed to more accurately assess the impact of donor smoke exposure on PGD and mortality using quantitative smoke exposure biomarkers. Methods: We performed a multicenter prospective cohort study of lung transplant recipients enrolled in the Lung Transplant Outcomes Group cohort between 2012 and 2018. PGD was defined as grade 3 at 48 or 72 hours after lung reperfusion. Donor smoking was defined using accepted thresholds of urinary biomarkers of nicotine exposure (cotinine) and tobacco-specific nitrosamine (4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol [NNAL]) in addition to clinical history. The donor smoking-PGD association was assessed using logistic regression, and survival analysis was performed using inverse probability of exposure weighting according to smoking category. Measurements and Main Results: Active donor smoking prevalence varied by definition, with 34-43% based on urinary cotinine, 28% by urinary NNAL, and 37% by clinical documentation. The standardized risk of PGD associated with active donor smoking was higher across all definitions, with an absolute risk increase of 11.5% (95% confidence interval [CI], 3.8% to 19.2%) by urinary cotinine, 5.7% (95% CI, -3.4% to 14.9%) by urinary NNAL, and 6.5% (95% CI, -2.8% to 15.8%) defined clinically. Donor smoking was not associated with differential post-lung transplant survival using any definition. Conclusions: Donor smoking associates with a modest increase in PGD risk but not with increased recipient mortality. Use of lungs from smokers is likely safe and may increase lung donor availability. Clinical trial registered with www.clinicaltrials.gov (NCT00552357).

    Citation

    Joshua M Diamond, Edward Cantu, Carolyn S Calfee, Michaela R Anderson, Emily S Clausen, Michael G S Shashaty, Andrew M Courtwright, Laurel Kalman, Michelle Oyster, Maria M Crespo, Christian A Bermudez, Luke Benvenuto, Scott M Palmer, Laurie D Snyder, Matthew G Hartwig, Jamie L Todd, Keith Wille, Chadi Hage, John F McDyer, Christian A Merlo, Pali D Shah, Jonathan B Orens, Gundeep S Dhillon, Ann B Weinacker, Vibha N Lama, Mrunal G Patel, Jonathan P Singer, Jesse Hsu, A Russell Localio, Jason D Christie. The Impact of Donor Smoking on Primary Graft Dysfunction and Mortality after Lung Transplantation. American journal of respiratory and critical care medicine. 2024 Jan 01;209(1):91-100

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37734031

    View Full Text